We modified the traditional 2-aryl-4-aminoquinazoline structure of fourth-generation EGFR inhibitors. As a result, we were able to create a number of novel 2-aryl-4-aminothienopyrimidine derivatives (A1–A45), as well as identify key sites that affect the backbone′s bioactivity but were not previously explored. These sites could be used as references by future researchers.

中文翻译：

---

克服 EGFRDel19/T790M/C797S 突变的见解：2-芳基-4-氨基噻吩并嘧啶主链的视角

我们对第四代EGFR抑制剂传统的2-芳基-4-氨基喹唑啉结构进行了修饰。因此，我们能够创造出许多新型 2-芳基-4-氨基噻吩并嘧啶衍生物 ( A1-A45 )，并确定了影响主链生物活性但之前未探索过的关键位点。这些网站可以作为未来研究人员的参考。